OneSource Pharma adds RPT details to AGM notice for Sept 23 meeting
- OneSource Specialty Pharma issued an addendum to its 19th AGM notice dated July 24, 2026
- Additional disclosures relate to RPTs with Strides Pharma Science Limited and its US subsidiary
- Audit Committee reviewed CEO/CFO certificates as per Industry Standards for RPTs
- The 19th AGM is scheduled for September 23, 2026, via Video Conferencing

*this image is generated using AI for illustrative purposes only.
OneSource Specialty Pharma issued an addendum to the notice of its 19th Annual General Meeting scheduled for September 23, 2026. The company disclosed additional information regarding material related party transactions with Strides Pharma Science Limited and Strides Pharma Inc, USA.
The addendum forms an integral part of the original AGM notice dated July 24, 2026. It specifically addresses Item No. 6 and Item No. 7 of the agenda, which seek shareholder approval for these transactions. Strides Pharma Inc is a wholly owned subsidiary of Strides Pharma Science Limited.
Compliance Disclosures
The Audit Committee has reviewed the certificates provided by the Chief Executive Officer and Chief Financial Officer of the listed entity. These reviews were conducted in accordance with Industry Standards pertaining to Related Party Transactions (RPTs).
The meeting will be held via Video Conferencing at 5:00 pm IST. The company uploaded the addendum to its website and submitted it to BSE Limited and National Stock Exchange of India Limited for records.
Historical Stock Returns for Onesource Specialty Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.27% | +0.44% | +3.69% | +8.67% | -14.02% | -6.48% |
What specific strategic synergies or cost-saving measures does OneSource anticipate from these related party transactions with Strides Pharma?
How might the approval of these transactions influence OneSource's future capital allocation and R&D investment priorities?
Are there potential regulatory hurdles or antitrust concerns associated with the deepening ties between OneSource and Strides Pharma Science Limited?


































